Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Related BMY
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Thursday Morning Earnings Reports
Drug Giants Advance Cancer Treatments (Fox Business)
Related MRK
Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties
Pharmaceutical ETFs Are Health Care Sector Standouts
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Most Popular

Related Articles (BMY + MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters